Page 3 - Peer Perform News Today

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16.

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of Reliance Steel & Aluminum Co. ...

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

American Airlines’ earnings could determine whether the stock’s recent bounce can continue.

Northrop Grumman Corporation (NYSE: NOC) is expected to release earnings results for its fourth quarter, before the opening bell on Jan. 25, 2024.

U.S. stocks closed higher on Friday, with the S&P 500 settling at an all-time high during the session. All three major indices are now in positive zone for 2024.

AMD downgraded, American Airlines upgraded: Wall Street's top analyst calls

U.S. stocks closed higher on Friday, with the S&P 500 settling at an all-time high during the session. All three major indices are now in posi...

Here are Monday's biggest calls on Wall Street.

Wolfe Research analyst, Deepak Mathivanan, that the company could be a potential acquisition target for Uber.